Mississippi Oncology Society

03/16/2026

https://bluetoad.com/publication/?i=862064&p=1&view=issueViewer
MOS Insights for March

Easily create responsive digital editions and microsites using BlueToad's digital publishing platform. Simply upload your PDFs to make your content desktop and mobile friendly or create new content directly on our easy-to-use content publishing platform.

03/05/2026

On March 5, 2026, the Food and Drug Administration approved teclistamab (Tecvayli, Janssen Biotech, Inc.) in combination with daratumumab hyaluronidase-fihj for

02/26/2026

FDA granted accelerated approval to zongertinib, a kinase inhibitor, for an expanded indication for adults with certain lung cancers.

02/24/2026

FDA grants traditional approval to encorafenib for metastatic colorectal cancer with a BRAF V600E mutation

02/20/2026

FDA approves acalabrutinib with venetoclax for chronic lymphocytic leukemia or small lymphocytic lymphoma

02/17/2026

https://bluetoad.com/publication/?i=860900&p=1&view=issueViewer&pp=1
February issue of MOS Insights is here.

February 2026 Insights newsletters are published by Bay Media, Inc. as part of Strategies Magazine . To advertise contact adsales@strategiesoncology.com | 410 -647-8402 MSDH Unveils 2025 Public Health Report Card On Wednesday January 21, 2026, MS Department of Health (MSDH) and the Mississippi State...

02/10/2026

Full prescribing information for Keytruda and Keytruda Qlex will be posted on Drugs@FDA.

02/05/2026

The U.S. Food and Drug Administration (FDA) is providing this communication to increase awareness of recent updates to the product labeling of capecitabine (Xeloda) and fluorouracil (5-FU) related to risks associated with dihydropyrimidine dehydrogenase (DPD) deficiency. All healthcare providers sho

02/05/2026

PBM bill HB 1665 has many important components to improve transparency, prohibit spread pricing, return rebates back to plan sponsor, make reimbursement no less than acquisition price, prohibit steering, oversight from Dept of Insurance, allow the plan sponsor and state health plan to define specialty drugs. It would repeal in 3 years but plenty of time to produce data and show impact of these measures.

Independent pharmacists have warned that if legislators do not pass reform legislation, pharmacies may be forced to close.

02/04/2026

MOS working with some of our corporate partners from AstraZeneca and BMS at the Mississippi Capitol. Appreciate their support of two biomarker testing bills moving in both Chambers! Pictured from left are Jim DeLatte, Angela Ladner, Michele Guadalupe and Jesse Lewis.

01/29/2026

https://www.facebook.com/share/p/1AwkNPQ9Mu/?mibextid=wwXIfr
This was one of over 50 recommendations which came from the Mississippi Comprehensive Cancer Control Coalition Task Force that MOS helped administer. Proud to see patient driven issues being addressed by our Legislators. Special thanks to Rep Sam Creekmore and Rep Kevin Felsher for their commitment to seeing this bill become law during this session.

The Mississippi House of Representatives unanimously passed legislation Wednesday that would require state-regulated health insurance plans to cover biomarker

01/27/2026

On January 27, 2026, the Food and Drug Administration approved daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech, Inc.) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for adults with newly diagnosed multiple myeloma who are ineligible for autologous stem cel